Highest-materiality recent filing
Selectis Health completes merger with Black Pearl Equities II; shareholders receive $5.75 per share
On October 5, 2026, Merger Sub merged into Selectis Health, Inc.; Selectis became a wholly owned subsidiary of Black Pearl Equities II, LLC and an indirect subsidiary of Parent.
Black Pearl completes tender offer for Selectis Health at $5.75/share; 90.93% tendered
2,789,027 shares (90.93%) validly tendered; all conditions satisfied, payment to proceed.
Selectis Health to be acquired by Black Pearl for $5.75 per share in cash
Selectis Health stockholders to receive $5.75 per share in cash in acquisition by Black Pearl Equities affiliates.
CEO/CFO Adam Desmond resigns; Krystal Eckhart appointed interim CEO and CFO
Adam Desmond resigned as CEO, CFO, and board member effective May 14, 2026.
Selectis Health sells two Georgia SNFs for $15.7M; net proceeds ~$9M
Sold Glen Eagle Healthcare (101-bed, Abbeville) and Eastman Healthcare (100-bed) to GA SNF entities.
Selectis Health agrees to sell two Georgia skilled nursing facilities for $15.7M
Purchase price $15.7M for Glen Eagle (101-bed) and Eastman (100-bed) facilities in Georgia.
Selectis Health sells two Georgia skilled nursing facilities for $13.175 million
Sold Sparta (71-bed) and Warrenton (110-bed) facilities for aggregate $13.175M; escrow of $1.3M.
Selectis Health extends $1.775M notes to Feb 2026, interest rate raised to 13%
Maturity extended to Feb 28, 2026 or earlier upon Qualified Transaction; 30-day extensions possible with 0.5% fee.
Selectis Health agrees to sell two Georgia skilled nursing facilities for $13.175M
Total purchase price $13,175,000 for 71-bed Sparta and 110-bed Warrenton facilities.
Purchaser terminated the Purchase and Sale Agreement and Operations Transfer Agreement for Georgia subsidiaries effective July 13, 2025.
Selectis Health signs $27M deal to sell four Georgia skilled nursing facilities
Purchase agreements cover Glen Eagle (101 beds), Eastman (100 beds), Sparta (71 beds), and Warrenton (110 beds).
Selectis Health's auditor Marcum LLP resigns; going concern opinion issued for 2022/2023
Marcum LLP terminated as independent auditor effective November 20, 2024.
Selectis Health sells Georgia skilled nursing facility for $6.75M, reduces debt
Sold Archway Transitional Care Center 1 in Macon, GA for $6.75M; buyer was lessee since 2016.
Selectis Health signs definitive agreement to sell Archway nursing facility for $6.75M
Wholly-owned subsidiary Goodwill Hunting, LLC (seller) entered PSA to sell Archway Property in Macon, GA to Bibb County Holdings II, LLC for $6.75M.
Selectis Health subsidiary agrees to sell Archway Transitional Care Center for $6.75M
Purchase price of $6,750,000 for skilled nursing facility in Macon, GA.
Selectis Health appoints Adam Desmond as permanent CEO effective March 18, 2024
Board of Directors appointed Adam Desmond as Chief Executive Officer, effective March 18, 2024.
Selectis Health's sale of Georgia subsidiaries terminated by purchaser; company denies defaults
Effective Feb 20, 2024, Purchaser terminated the Purchase & Sale and Operations Transfer Agreements for certain Georgia subsidiaries without consummation.
Selectis Health appoints Jim Creamer interim CFO, Clifford Neuman to board
Jim Creamer appointed Interim CFO effective Dec 18, 2023; annual salary $120,000.
CEO Lance Baller resigns; board member Adam Desmond named Interim CEO
Lance J. Baller resigned as CEO, acting principal financial officer, and director effective Nov 13, 2023 or earlier upon replacement.
Selectis Health President and COO Christopher Barker resigns effective May 31 due to health issues
Christopher 'Randy' Barker resigned as President, COO, and board member effective May 31, 2023.
CFO Christine Lucus resigns effective April 5, 2023; CEO Lance Baller interim PFO
Christine Lucus resigned as CFO, effective April 5, 2023.
Selectis Health Q2 revenue up 91% to $11.5M; net income $1.0M vs loss year ago
Q2 2022 revenue $11.5M (record), up 91% YoY; net income $1.0M ($0.34 per share) vs net loss of $0.7M.
In accordance with Section 2.10 of the Merger Agreement, at the Effective Time, each of Clifford L. Neuman, Kent J. Lund, and Richard Huebner ceased to serve as a member of the Board of Directors of the Company (the “Board”) and of any committee of the Board, and Krystal Eckhart ceased to serve as Interim Chief Financial Officer of the Company.
In accordance with Section 2.10 of the Merger Agreement, at the Effective Time, Abraham Schwartz and Zalman Schapiro, being the directors of Merger Sub immediately prior to the Effective Time, became the directors of the Company, and Abraham Schwartz and Zalman Schapiro, being the officers of Merger Sub immediately prior to the Effective Time, became the officers of the Company.
and Abraham Schwartz and Zalman Schapiro, being the officers of Merger Sub immediately prior to the Effective Time, became the officers of the Company.
In accordance with Section 2.10 of the Merger Agreement, at the Effective Time, Abraham Schwartz and Zalman Schapiro, being the directors of Merger Sub immediately prior to the Effective Time, became the directors of the Company, and Abraham Schwartz and Zalman Schapiro, being the officers of Merger Sub immediately prior to the Effective Time, became the officers of the Company.
In accordance with Section 2.10 of the Merger Agreement, at the Effective Time, each of Clifford L. Neuman, Kent J. Lund, and Richard Huebner ceased to serve as a member of the Board of Directors of the Company (the “Board”) and of any committee of the Board, and Krystal Eckhart ceased to serve as Interim Chief Financial Officer of the Company.
In accordance with Section 2.10 of the Merger Agreement, at the Effective Time, each of Clifford L. Neuman, Kent J. Lund, and Richard Huebner ceased to serve as a member of the Board of Directors of the Company (the “Board”) and of any committee of the Board, and Krystal Eckhart ceased to serve as Interim Chief Financial Officer of the Company.
and Abraham Schwartz and Zalman Schapiro, being the officers of Merger Sub immediately prior to the Effective Time, became the officers of the Company.
In accordance with Section 2.10 of the Merger Agreement, at the Effective Time, each of Clifford L. Neuman, Kent J. Lund, and Richard Huebner ceased to serve as a member of the Board of Directors of the Company (the “Board”) and of any committee of the Board, and Krystal Eckhart ceased to serve as Interim Chief Financial Officer of the Company.
On May 15, 2026, the Board of Directors of the Company appointed Krystal Eckhart to serve as the Company’s Interim CEO and CFO.
Effective May 14, 2026 the Board of Directors of Selectis Health, Inc., a Utah corporation (the “Company”) and Adam Desmond (“Desmond”) agreed that he would resign all positions with the Company including CEO, CFO of the Company and a member of the Board of Directors.
Adam Desmond, the Company’s current CEO, will serve as the Interim CFO until a permanent CFO is identified.
On January 17, 2025, James Creamer tendered his resignation as Chief Financial Officer of Selectis Health, Inc. (the “Company”), pursuant to a Separation Agreement and Release of even date.
Max materiality 1.00 · Median 0.50 · Most common event leadership